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Abstract
Conventional assays for quantification of allo-reactive T-cell precursor frequencies (PF) are relatively insensitive. We present
a robust assay for quantification of PF of T-cells with direct donor-specificity, and establish the kinetics of circulating donor-
specific T cells after liver transplantation (LTx). B cells from donor splenocytes were differentiated into professional antigen-
presenting cells by CD40-engagement (CD40-B cells). CFSE-labelled PBMC from LTx-recipients obtained before and at
several time points after LTx, were stimulated with donor-derived or 3rd party CD40-B cells. PF of donor-specific T cells were
calculated from CFSE-dilution patterns, and intracellular IFN-c was determined after re-stimulation with CD40-B cells.
Compared to splenocytes, stimulations with CD40-B cells resulted in 3 to 5-fold higher responding T-cell PF. Memory and
naı¨ve T-cell subsets responded equally to allogeneic CD40-B cell stimulation. Donor-specific CD4+ and CD8+ T-cell PF ranged
from 0.5 to 19% (median: 5.2%). One week after LTx, PF of circulating donor-specific CD4+ and CD8+ T cells increased
significantly, while only a minor increase in numbers of T cells reacting to 3rd party allo-antigens was observed. One year
after LTx numbers of CD4+ and CD8+ T cells reacting to donor antigens, as well as those reacting to 3rd party allo-antigens,
were slightly lower compared to pre-transplant values. Moreover, CD4+ and CD8+ T cells responding to donor-derived, as
well as those reacting to 3rd party CD40-B cells, produced less IFN-c. In conclusion, our alternative approach enables
detection of allo-reactive human T cells at high frequencies, and after application we conclude that donor-specific T-cell PF
increase immediately after LTx. However, no evidence for a specific loss of circulating T-cells recognizing donor allo-antigens
via the direct pathway up to 1 year after LTx was obtained, underscoring the relative insensitiveness of previous assays.
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Introduction
After allogeneic transplantation, recognition of major allo-
antigens by recipient T-cells occurs via two different pathways: 1)
the direct pathway whereby intact donor MHC is presented by
donor-derived Antigen-Presenting Cells (APC) to recipient T cells;
2) The indirect pathway, whereby processed donor MHC is
presented to recipient T cells as peptides on self-MHC molecules
expressed on self-APC [1,2].
Direct pathway T cells are activated by donor-derived APC that
migrate from the graft into recipient secondary lymphoid tissues
[3,4,5,6]. Animal studies have shown that donor APC migration is
a transient phenomenon after transplantation [3,5]. Recently, we
observed that a similar transient migration of donor-derived APC
into recipients occurs after liver transplantation (LTx) in humans
[7]. Therefore, the general presumption is that direct pathway
responses dominate during the early post-transplant period, but
subside thereafter [2]. However, due to their cross-sectional approach
[8,9,10,11,12,13] not any study has described the kinetics of recipient
T-cell alloreactivity after organ transplantation in humans in detail.
A common assumption is that frequencies of allogeneic T cells
stimulated by the direct pathway are 100- to 1000-fold higher than
responses to pathogens [2,14]. Animal studies showed that
frequencies of T cells with direct allo-specificity range between
0.01 and 21% [15,16,17,18,19,20,21]. However, the reported
alloreactive T cell frequencies in humans are generally lower,
ranging from 0.001 to 0.1% [8,12,13,22,23]. This raises the
question if this difference in reported frequencies is due to an
underestimation of alloreactive T cells in humans caused by
suboptimal sensitivity of conventional assays.
Traditionally, allo-reactive T cells have been quantified by
limiting dilution analysis (LDA). It is now known that LDA detect
frequencies of pathogen-specific T cells that are one to two logs
lower than those detected by MHC tetramer staining [24,25].
Hence, a more robust assay for quantification of alloreactive human
T cells is required. Because the restricted availability of MHC-
tetramers (especially of MHC class II tetramers) is insufficient to
cover the enormous heterogeneity of HLA, and the knowledge of
peptides involved in direct pathway allo-recognition is limited [26],
we chose an alternative approach.
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The first aim of the present study is to set up a sensitive assay for
quantification of frequencies of direct pathway alloreactive T cells.
For this purpose, we used CD40-activated donor-derived B cells
instead of donor leukocytes from spleen or blood, as stimulator
cells, and calculated frequencies of responding recipient T-cells
from division patterns measured by flow cytometric analysis of
carboxyfluorescein succinimidyl ester (CFSE) fluorescent dye
dilution. CFSE-dilution has a sensitivity similar to MHC-tetramer
staining [27] [28,29,30], and CD40-B cells are a uniform source
of professional APC [31,32,33,34]. The second aim was to deter-
mine the kinetics of the direct pathway allo-response after liver
transplantation by applying this assay.
Materials and Methods
Ethics Statement
The Ethics committee of the Erasmus Medical Center has
approved the collection of blood in patients after liver transplan-
tation for immunologic monitoring. A written consent from patients
was obtained prior to the study.
Patients
The study of the longitudinal kinetics of the direct allo-response
included 13 patients who underwent an orthotopic liver trans-
plantation between 1997 and 2000 at Erasmus University Medical
Centre, and had stable graft function up to 1 year after LTx. All
patients received a graft from a deceased donor. Indication for
LTx was: post-alcoholic liver cirrhosis (n = 4), primary sclerosing
cholangitis (n = 4), chronic hepatitis C (n = 1), chronic hepatitis B
(n = 1), auto-immune hepatitis (n = 1), Morbus Wilson (n = 1), and
heamangio-endothelioma (n = 1). In addition, we measured the
allo-response in 5 additional patients before and at 1 year after
LTx. Indications for LTx in these patients were: primary
sclerosing cholangitis (n = 1), chronic hepatitis B (n = 2) and
polycystic liver disease (n = 2). Initial immunosuppressive therapy
consisted of cyclosporine A (CsA) or tacrolimus together with
prednisone, and with or without azathioprine. Patient follow up
was at least one year.
Patient and donor cells
Splenic tissue from donors was obtained during multi-organ
donation procedure, and single cell suspensions were made.
Venous blood from patients was collected before transplantation
and at several time points after transplantation. For optimization
of the assay conditions, blood from healthy individuals was
obtained from the blood bank. Peripheral Blood Mononuclear
Cells (PBMC) and splenocytes were isolated by Ficoll-Hypaque
density gradient centrifugation and stored frozen in 10% DMSO
solution.
CD40-B cell generation
B cells were expanded from donor splenocytes or recipient
PBMC using a mouse fibroblast cell line stably transfected with
human CD40L (L-CD40L) that was kindly provided by prof. Cees
van Kooten (LUMC, Leiden, The Netherlands) [35]. L-CD40L
cells were irradiated (52 Gy) and plated on 6-well plates (Costar,
Cambridge, USA) at a concentration of 0.26106 cells per well in
medium containing RPMI 1640 (Lonza, Basel, Switzerland), 10%
heat inactivated FCS (Sigma-Aldrich, St Louis, US) and 1%
penicillin/streptomycin (Gibco, California, USA). After overnight
culture, L-CD40L cells were rinsed with RPMI. PBMC were seeded
at 16106 cells/ml IMDM (Lonza) with 10% heat inactivated
human male AB serum (Lonza), 1% penicillin/streptomycin and
1% insulin-transferrin-selenium solution (Gibco) (B-cell medium) on
L-CD40L cells. Recombinant human interleukin-4 (rhIL-4)
(40 IU/ml) (Strathmann Bioscience, Germany) and CsA (1 mg/
ml) (Novartis, Basel, Switzerland) to prevent T-cell expansion were
added. Every 3–4 days the cultured cells were transferred to freshly
irradiated L-CD40L cells in a ratio of 1 CD40L cell: 4 CD19+ cells.
Proportions of B- and T cells were checked at regular inter-
vals. When the percentage CD19+ cells was .85%, CsA was
discontinued for at least 3 days before their use in T-cell stimulators.
When the purity of CD19+ cells was.95%, CD40-B cells were used
in assays.
CFSE-MLR
Before labeling with CFSE (Invitrogen, Paisley, UK), PBMC were
thawed and recovered during overnight culture at 37uC with 5%
CO2. Labeling was performed with 0.5 mM CFSE. CFSE-labeled
PBMC (16105) were stimulated with 26105 irradiated (30 Gy) donor
CD40-B cells, third party CD40-B cells, or autologous PBMC-
derived CD40-B cells in 96-wells U-bottom plates in a final volume of
200 ml B-cell medium. Each assay was performed in triplicate. PHA-
stimulated recipient PBMC were included as positive controls to test
viability of thawed PBMC. Results were only included if PBMC
showed responsiveness to PHA. Unless otherwise stated in the results
section, flow cytometric analysis was performed after 6 days of culture
at 37uC and 5% CO2. In quadruple experiments of the additional 5
patients, T cells were restimulated at day 5 of culture with donor-
derived or 3rd party-derived CD40-B cells for 24 hours, and during
the last 15 hours Brefeldin A (Sigma) was added to enable measure-
ment of IFN-c production.
Data Analysis with ModFitH Software
Precursor frequencies were calculated using ModFit LTH
software (Verity Software House, USA). The basic principles of
the calculation model of the program are that the cell number
duplicates at each division and that CFSE is equally distributed
over the daughter cells, resulting in a two-fold reduction of the
CFSE intensity after each division cycle [36] as explained in
Figure 1. The software calculates backwards the precursor frequency
(PF), which is the proportion of the total cells calculated to have
been present at the start of the experiment that responded to the
allo-stimulus by dividing. Because the width of the intensity
histogram of T cells in the parent generation spreads slowly during
culture, it is difficult to differentiate cells that have divided once
from non-divided cells. Supported by other studies [28,37], we
considered cells that had undergone at least two divisions as
responders in our data analysis. Only ModFitH plots with a
reduced chi-square (which is a measurement for the association of
the calculated model and the real CFSE-dilution histogram: or in
other words, a measurement for the fit of the model into the
dilution histogram) smaller than 5 were included in the analysis.
Mean PF were calculated from triplicate cultures. To assess the
accuracy of the technique, we calculated the coefficient of
variation of triplicates in 6 patients using the following formula:
SDtriplicate/mean triplicate.
FACS data acquisition
Cultured cells were stained for 15 minutes at room temperature
in 96-wells U-bottom plates with appropriate concentrations of
CD3-PE (Biolegend, San Diego, USA), CD4-APC (eBioscience,
San Diego, US) and CD8-Pacific Blue (BD Biosciences, San Jose,
CA, USA) antibodies in a final volume of 50 ml PBS. In indivi-
dual experiments indicated in the Results section, cultured cells
were stained with CD8-Pacific Blue mAb, after which cells were
fixed and permeabilized with Fix & PermH reagent (ADG Bio
Research GmbH, Vienna, Austria) and incubated with PE-labeled
Direct Pathway Kinetics
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anti-granzyme B (Sanquin, Amsterdam, The Netherlands) and
anti-perforin (BD Pharmingen) mAb to analyze intracellular
expression of cytotoxic molecules. 7AAD (BD Biosciences, San
Jose, CA, USA) was added just before measurement started to
exclude dead cells. In experiments in which T cells were re-
stimulated with donor-derived or 3rd party-derived CD40-B cells
during the last 24 hours of culture, intracellular IFN-c was
measured upon permeabilization with Fix & PermH (An der Grub,
Vienna, Austria) reagent and labeling with PeCy7-conjugated anti-
IFN-c (eBisocience, San Diego, US). Data acquisition was
performed with a Canto II Flowcytometer from BD Biosciences
(San Jose, CA, US).
FACS sorting
PBMC from healthy subjects (2006106) were labeled in PBS
with sterile CD14-PE (BD Biosciences, San Jose, US), anti-
BDCA1-PE (Miltenyi, Bergisch Gladbach, Germany), CD19-PE,
CD123-PE, CD56-PE, CD45RA-FITC and CD45RO-APC (all
from Beckman Coulter, Miami, US) in a final volume of 500 ml for
30 minutes at 4uC, followed by a double wash step with 3 ml PBS
(Lonza). The cell pellet was resuspended to a concentration of
506106 PBMC/ml PBS. Naı¨ve and memory T-cell populations
were sorted with a FACS Aria (BD Biosciences, San Jose, CA,
USA) by exclusion of PE-positive cells and gating on the CD45-
RAhigh and CD45-ROhigh cells. CD3+ purity was checked after
sorting with CD3-PerCP-Cy5 (Biolegend, San Diego, US).
IFN-c ELISPOT
LTx-recipient PBMC (26105) were pre-incubated in a 12-wells
culture plate at 37uC and 5% CO2 with 4610
5 splenocyte-derived
CD40-Bcells in a final volume of 600 ml B-cell medium. After
48 hours cells were harvested, washed twice with PBS and re-
suspended in 200 ml of B-cell medium. Cells were transferred
to two Elispot wells coated with anti-IFN-c antibody, and incu-
bated in a final volume of 100 ml per well for 5 hours at 37uC.
Subsequently, the Elispot assay (U-Cytech Biosciences, Utrecht,
The Netherlands) was executed according the manufacturers
protocol. Spot analysis was performed with a Bioreader 3000
Elispot reader (Biosys, GmbH, Karben, Germany). Because of
preparation-induced cell death, we based our frequency calcula-
tions on the hypothesis that eventually 56104 recipient PBMC
were transferred to each of the two coated Elispot wells.
Statistics
Differences between groups were analyzed using the Wilcoxon
test and were considered statistically significant if the p-value was
#0.05.
Results
CD40-B cells expand and differentiate from splenocytes
and PBMC into professional antigen presenting cells
Within 21 days, co-culture of human splenocytes or PBMC with
L-CD40L cells in the presence of IL-4 and CsA resulted in a 104-
fold increase of total B-cell numbers, followed by a decrease after
27 days (Figure 2A). The decrease was due to loss of CD40
expression on CD40-B cells (data not shown). B-cell purity .95%
was reached between day 9 and 12. CD40-B cells did not only
expand, but also differentiated to professional APC, expressing
CD38 (activation marker), HLA-DR and co-stimulatory molecules
(Figure 2B). Contrary, human splenocytes contained 4765%
HLA-DR+ APC, of which only a small fraction expressed co-
stimulatory molecules (CD80+: 0.960.9%, CD86+: 7.165.2%;
n = 6) (Figure 2C), indicating that CD40-B cells are a more
uniform preparation of APC. CD40-B cells did not differentiate to
plasma cells, as all cells lacked CD138.
Optimization and validation of CFSE-MLR
To determine the optimal culture period for quantification of
T cells reacting to allogeneic stimulation with CD40-B cells,
Figure 1. Analysis of CFSE-dilution patterns by ModFitH software. ModFit-derived CFSE-pattern of CD3+ T cells after 6 days of stimulation
with allogeneic CD40-B cells. The software draws peaks within the CFSE-histogram centered on halving intensity values from the parental peak CFSE-
intensity. Non-divided T cells are CFSEhigh and are depicted blue, while the peaks left from it correspond to divided cells. Based on the enumerated
proportions of T cells detected in each generation ( =% under each peak) and the total number of CD3+ T cells analyzed by the flowcytometer, the
program calculates the absolute numbers of daughter T cells in each generation. The numbers of precursors which gave rise to the daughter cells are
extrapolated by dividing the absolute numbers of T cells in each generation by 2n, in which n stands for the division cycle ( = absolute # of
precursors). The PF is calculated by dividing the numbers of precursors from generation 2 onwards ( = B) by the total number of precursors in all
generations including the parent peak and generation 1 ( = A). In this example the calculated PF = (362,302 – (337,620 + 8925)/362,302)6100= 4.3%.
The fit of the derived Gaussian peaks in the CFSE-dilution pattern is indicated by the reduced chi-square value. Values below 5 were considered as a
good fit according to the manufacturer’s instructions, and were included in the analysis.
doi:10.1371/journal.pone.0014452.g001
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CFSE-dilution patterns of CD3+, CD4+ and CD8+ cells were
analyzed daily till day 7 of culture using ModFitH software.
Proliferation of T cells started at day 4, and new T cells were
recruited to proliferate until day 5, thereafter PF reached a plateau
value (Figure 3A). After day 6 PF increased again, which is
probably due to non-specific bystander activation [27]. Therefore,
we decided to determine PF at day 6 of culture. CD8+ T cells
acquired cytolytic molecules from day 4 onward, and at day 7
about 50% of CD8+ T-cells that proliferated in response to
allogeneic CD40-B cells ( = CFSElow CD8+ T cells) expressed
granzyme B and/or perforin, indicating that they had acquired
cytolytic effector function (Figure 3B).
In calculating PF, ModFitH assesses the total number of T cells
at the start of the allogeneic stimulation using backward
calculation from the cells analyzed at the end of the culture. In
contrast, LDA and ELISPOT calculate PF based on the numbers
of T cells that are put into culture. To assess whether this
difference would influence the outcomes of the different
approaches of calculating PF, we counted daily the numbers of
vital PBMC and calculated the proportions of CD3+, CD4+ and
CD8+ T cells in CD40-B cell-stimulated CFSE-MLR. Figure 3C
shows that numbers of all T-cell subsets decreased during the first
2 days of cultures by 36% for the CD3+, 34% for the CD4+ and
38% for the CD8+ T cells, a phenomenon called preparation-
induced cell death [38]. Thereafter, numbers of T cells increased.
Most likely, T cells alive at day 2 are the real starting population
from which allo-reactive T cells are recruited to proliferate,
suggesting that LDA and ELISPOT underestimate PF, while
CFSE-based assays may yield more accurate PF.
Comparison of CD40-B cells with conventional
splenocytes as stimulators in CFSE-MLR and comparison
of CFSE-MLR with IFN-c ELISPOT
To compare the efficacy of CD40-B-cells with conventional
splenocyte stimulation, CFSE labeled PBMC from patients were
co-cultured with donor splenocyte-derived CD40-B cells or with
non-manipulated splenocytes from the same donor. Figure 4A
displays that at day 6 T cells responded abundantly to stimu-
lation with CD40-B cells, while splenocyte stimulation resulted
in a much lower response. The results of paired comparisons
between stimulations of LTx recipient PBMC with CD40-B
cells or splenocytes are summarized in Figure 4B and C.
Although stimulation with autologous CD40-B cells also resulted
in T-cell proliferation, responses to allogeneic CD40-B cells
were significantly higher (4B). The PF of T cells specifically
responding to donor-derived CD40-B calculated in this ways were
6.8 fold, 5.9-fold and 8.6-fold higher PF for CD3+, CD4+ and
CD8+ T cells, respectively, compared to specific responses to
donor-derived splenocytes. Specific allogeneic responses to donor-
derived CD40-B cells were calculated by subtraction of PF
reacting to autologous CD40-B cells, and specific allogeneic
responses to donor splenocytes by subtraction of PF of unstimu-
lated T cells (4C). These data also reveal that comparable
proportions of alloreactive precursors are detected within CD4+
and CD8+ subsets upon CD40-B cell stimulation (median PF:
6.4% 64.0 for the CD4+ and 8.45% 65.4 for the CD8+
subpopulation). Finally, CD40-B cell stimulation resulted in less
variation between triplicate PF measurements than splenocyte
stimulation; the coefficient of variation of measured triplicates was
3-fold lower (Figure 4D).
To enable comparison of CFSE-MLR with IFN-c ELISPOT, at
day 5 of culture we re-stimulated recipient PBMC for 24 hours
with CD40-B cells of the same donor, added Brefeldin A during
the last 15 hours, and measured intracellular IFN-c expression at
day 6. Interestingly, IFN-c was only produced by T cells that had
divided, but not all dividing cells produced IFN-c (Figure 4E). In
parallel, samples of the same PBMC were analyzed for IFN-c
production upon stimulation with the same CD40-B cells in IFN-c
ELISPOT. The percentages IFN-c-producing CD3+ T cells
detected in CFSE-MLR were considerably higher than the
percentages of IFN-c producing cells detected in ELISPOT,
showing that CFSE-MLR is more sensitive to detect IFN-c
producing T cells upon allogeneic stimulation than ELISPOT
(Figure 4F).
Figure 2. Expansion and differentiation of B cells using L-CD40L cells. A. Human splenocytes or PBMC were co-cultured with L-CD40L cells,
IL-4 and CsA. Within 3 weeks, a 104 fold increase of the numbers of B cells was obtained with a purity of .95%. T cells did not expand due to the
presence of CsA. The current graph represents expansion from PBMC, splenocytes gave similar results. B. Cell surface marker expression on CD40-B
cells harvested at day 12 of culture. CD40L-expanded B cells were activated (CD38+) and expressed the co-stimulatory molecules CD80 and CD86, and
MHC class-II, indicating that they became professional APC. However, they did not become plasma cells, since they lacked CD138. Solid lines
represent the expression of surface markers at day 0; dotted lines represent the expression at day 12 after culture. C. Donor splenocytes contained
about 50% of HLA-DR+ APC, however these lacked CD80 and showed low expression of CD86.
doi:10.1371/journal.pone.0014452.g002
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Relative contributions of naı¨ve and memory T cells to the
alloresponse measured by CFSE-dilution
To dissect the contributions of naı¨ve (CD45RA+) or memory
(CD45RO+) T cells to the allogeneic responses measured by
CSFE-MLR upon stimulation with CD40-B cells, we sorted
CD3+CD45RA+ and CD3+CD45RO+ cells (Figure 5A) and
stimulated them separately with CD40-B cells. Figure 5B shows
that after 6 days of culture memory and naı¨ve subsets contributed
equally to the alloresponse, with median CD3+ T-cell PF of 6.7%
and 7.7%, respectively.
Kinetics of the direct pathway donor-specific T-cell
response after LTx
To determine the kinetics of donor-specific T cell reactivity after
LTx, we quantified PF of donor-specific T cells in PBMC of 13
LTx-recipients with stable graft function at 1 year after LTx, using
donor-spleen derived CD40-B cells as stimulators. PBMC were
collected before transplantation, and 1 week, 1 month, 3 months
and 1 year after transplantation. To evaluate the specificity of
variations in responses to donor allo-antigens, we stimulated
CFSE-labeled patient PBMC also with 3rd party spleen-derived
CD40-B cells or with CD40-B cells derived from autologous
PBMC. In all samples measured, PF of T cells reacting to
autologous CD40-B cells were low compared to PF of T cells
reacting to donor or 3rd party CD40-B cells. In addition,
autologous responses did not change over time after transplanta-
tion. On the contrary, the numbers of circulating T cells reacting
to donor-derived CD40-B cells increased significantly at 1 week
after LTx in all T-cell subsets, followed by a decrease to values
below pre-transplant levels 1 year after LTx (Fig. 6A). Variations
in T-cell PF reacting to 3rd party allo-antigens showed the same
trend, although the differences in PF between subsequent time
points were generally smaller, and the increases in the first week
after LTx were not significant in the separate CD4+ and CD8+ T-
cell subsets (Figure 6B). To correct variations in the response to
donor allo-antigens for nonspecific changes in numbers of
circulating allo-reactive T cells, we calculated the donor-specific
responses (relative response; RR) by dividing PF to donor antigens
by PF to third parties. Figure 6C shows that the RR significantly
increased in all T-cell subsets during the first week after LTx
compared to the pre-transplant levels (CD3+: 1.4-fold, CD4+: 1.3-
fold and CD8+: 1.1-fold), followed by a gradual decrease after
week 1. However, after correction for responses to 3rd party allo-
antigens, none of the donor-specific responses declined below pre-
transplant values.
In contrast to these data, conventional assays have generally
shown that stable organ transplant recipients develop donor-specific
T-cell hypo-responsiveness [8,9,10,11,13,22,39]. To ensure that the
our aberrant observation was not due to a limited patient sample
size, we analyzed donor-specific and third-party T-cell responses in
5 additional LTx-recipients before LTx and 1 year after LTx. When
the RR-values of all LTx-patients analyzed (n = 18) before and 1
year after LTx were compared, again no evidence for CD4+ and
CD8+ donor-specific T-cell hypo-responsiveness at 1 year after LTx
was obtained, although there was a tendency to slightly lower
donor-specific total CD3+ T-cell numbers 1 year after LTx
(Figure 6D).
Finally, we compared effector functions of T cells reacting to
donor- and 3rd party allo-antigens by measuring intracellular IFN-c
in 5 LTx-recipients before and 1 year after LTx. For this purpose we
re-stimulated T cells at day 5 of culture with donor-derived or 3rd
party-derived CD40-B cells for 24 hours and added during the last
15 hours Brefeldin A. The proportions of T cells producing IFN-c
in response to donor allo-antigens were decreased 1 year after LTx
compared to pre-LTx values. However, the same was true for IFN-c
responses to 3rd party allo-antigens, resulting in similar RR of IFN-c
producing cells in all T-cell subsets before and 1 year after LTx
(Figure 7). Together these data show a donor-specific increase in
direct pathway T cell PF immediately after LTx, followed by a non-
specific decline of allo-reactive T cells numbers to values slightly
below pre-transplant levels within the first year after LTx, but no
specific loss of circulating donor-specific T-cell clones.
Figure 3. Kinetics of allogeneic T-cell responses to CD40-B cell
stimulation. CFSE-labeled PBMC from a healthy individual were
cultured for 7 days with allogeneic splenocyte-derived CD40-B cells.
A. CFSE-dilution patterns of CD3+, CD4+, CD8+ T cells were analyzed
daily, and PF were calculated with ModFitH software. B. Intracellular
granzyme B and perforin expression were analyzed daily in CD8+ T cells.
Depicted are the percentages of CD8+CFSElow T cells that expressed
granzyme B and/or perforin. C. Absolute numbers CD3+, CD4+ and CD8+
T cells during co-culture of CFSE-labelled PBMC with allogeneic CD40-B
cells. Vital PBMC were counted daily using trypan blue, and proportions
of CD3+, CD4+ and CD8+ T cells were analyzed by flowcytometry.
Absolute numbers of T-cell subsets were calculated by multiplying the
number of vital PBMC with the proportions of T cells obtained from
flowcytometric analysis.
doi:10.1371/journal.pone.0014452.g003
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Discussion
Combining CFSE-dilution as a read out with CD40-B cells as
stimulator cells, we developed a robust assay that detects human T
cells with direct allospecificity at frequencies comparable to those
predicted by animal experiments and 1- to 3-logs higher than PF
detected with conventional LDA or ElLISPOT [19,20,21,40,41].
This CFSE-MLR assay is able to discriminate between CD4 and
CD8 PF and detects both naı¨ve and memory T-cell responses to
allo-antigens in the same culture. By application of this assay we
found that, even with immunosuppressive therapy, numbers of
circulating CD4+ and CD8+ T cells with direct donor-specificity
increase immediately after LTx, indicating that both subsets are
primed by the graft, followed by a gradual decrease within the first
year. Importantly, after correction of changes in responses to 3rd
party allo-antigens, no specific loss of donor-specific T cells was
observed, showing that CD4+ and CD8+ T cells with direct donor-
specificity persist in the circulation up to at least 1 year after LTx.
However, a non-specific decrease in frequencies of circulating allo-
reactive CD4+ and CD8+ T cells to values slightly below pre-
transplant values was observed 1 year after LTx, a well as a non-
specific decrease in their capacity to produce IFN-c.
The first improvement contributing to the robustness of the
described assay is utilizing CD40-B cells as stimulators, resulting in
3- to 5-fold higher PF compared to stimulations with spleno-
cytes. CD40-engagement induces B-cell differentiation into profes-
sional APC with uniform expression of co-stimulatory molecules,
that are able to prime both memory and naı¨ve T-cell reponses
[31,34,42,43,44] [45]. Contrary, splenocytes contain only about
50% APC, of which a minority express co-stimulatory molecules.
CD40-B cells can be expanded from thawed splenocytes or
PBMC, even when these have a low viability, and their expansion
enables repeated measurements of donor-specific T-cell reactivity
in cases of limited supply of donor cells. Importantly, the absence
of T cells within CD40-B cell preparations precludes that donor-
derived T cells are included in CFSE-profiles of responder T cells,
which would lead to wrong PF calculations.
The second improvement is the use of CFSE-dilution in
combination with software that calculates PF as a read-out
technique. Detection of responding cells by this technique is not
dependent on the number of progeny cells in each individual
culture, which in LDA may lead to underestimation of PF when
small clones of progeny cells remain undetected [17,24,25,46].
Moreover, estimated PF are not negatively influenced by
‘‘preparation-induced cell death’’ of responder T cells at the
beginning of the cultures, because PF are calculated from the sum
of precursors present at the end of the cultures instead from cell
input at the start of the culture. We showed that allogeneic
stimulations are prone to significant loss of responder T cells
during the first 2 days of culture. Since dying cells do not respond,
techniques calculating PF from numbers of cells present at the start
of the culture, like LDA and ELISPOT, underestimate actual PF
[38]. Conversely, the CFSE-MLR may overestimate PF if more
non-proliferating cells compared to proliferating cells die during
culture. It is difficult to analyze whether non-proliferating cells die,
but the appearance of a plateau phase of PF between day 5 and 6
Figure 5. Relative contributions of naı¨ve and memory T cells to the allo-response in CFSE-MLR upon stimulation with CD40-B cells.
CFSE-labelled naı¨ve CD3+CD45RA+and CD3+CD45RO+ memory T cells were isolated from PBMC of healthy individuals by flowcytometric sorting, and
stimulated with allogeneic CD40-B cells for 6 days. A. Purity of CD3+CD45RO+ and CD3+CD45RA+ T cells after sorting. B. PF of CD3+CD45RO+ and
CD3+CD45RA+ T cells proliferating upon stimulation with allogeneic CD40-B cells. Depicted are means 6 SD of data from two independent
experiments, each with 3 replicates.
doi:10.1371/journal.pone.0014452.g005
Figure 4. Comparison of CD40-B cell and splenocyte stimulation and comparison of CFSE-MLR with IFN-c ELISPOT. A. CFSE-labeled
PBMC from an LTx-recipient were stimulated for 6 days with allogeneic splenocyte-derived CD40-B cells or with splenocytes from the same donor.
Dot-plots and CFSE-dilution graphs of CD3+ T cells show increased T-cell proliferation upon stimulation with CD40-B cells compared to splenocytes.
Percentages in dot plots depict % dividing (CFSElow) T cells. Percentages in histograms are calculated PF. B: Paired comparisons of PF of LTx-recipient
CD3+, CD4+ and CD8+ T cells upon stimulation with donor-derived CD40-B cells, autologous patient CD40-B cells, splenocytes or without stimulus.
Sixty CFSE-labelled PBMC-samples of 6 LTx-recipients, obtained either before, or at different time points after transplantation, were stimulated with
donor-derived or autologous CD40-B cells or with splenocytes from the same donor for 6 days. Bars represent median values. C: Donor-specific T-cell
responses obtained by subtraction of PF reacting to autologous CD40-B cells from PF responding to donor-derived CD40-B cells, or subtraction of PF
in the absence of allo-antigen (negative controls) from PF responding to donor splenocytes. Bars represent median values. D: Paired comparisons of
the coefficients of variation of triplicate measurements of LTx-recipient CD3+ PF in 108 PBMC-samples of 6 LTx-recipients upon stimulation with
donor-derived CD40-B cells or donor-derived splenocytes. Bars represent median values. E. Flowcytometry dotplot showing CFSE-dilution versus
intracellular IFN-c of CD3+ T cells stimulated with autologous or allogeneic CD40-B cells, and re-stimulated at day 5 for 24 hours with CD40-B cells of
the same donor, the last 15 hours in the presence of Brefeldin A. Only T cells that divided (CFSElow) in response to allogeneic CD40-B cells produce
IFN-c. F. Comparison of CFSE-MLR with IFN-c ELISPOT. Four different CFSE-labeled PBMC samples from LTx-recipients were stimulated for 5 days with
allogeneic splenocyte-derived CD40-B cells, and re-stimulated for 24 hours with CD40-B cells of the same donor to detect intracellular IFN-c
expression. In parallel, samples of the same PBMC were analyzed for IFN-c production upon stimulation with the same CD40-B cells in IFN-c ELISPOT.
IFN-c-producing cells in ELISPOT are depicted as percentage of PBMC, while the percentages of IFN-c producing cells in CFSE-MLR are depicted as
percentages of CD3+ T cells.
doi:10.1371/journal.pone.0014452.g004
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of culture indicates that at least during this last phase of the
cultures no preferential death of non-proliferating T cells occurs.
ELISPOT also underestimates PF by ignoring allo-reactive T
cells that do not secrete the particular cytokine detected. Indeed,
we observed that not all T-cells that responded to allogeneic
CD40-B cells by cell division (as determined by CFSE-dilution)
produced IFN-c. In addition, our data show that the numbers of
IFN-c producing T cells detected in ELISPOT are considerably
lower compared to those detected by flowcytometry in CFSE-MLR,
demonstrating the lower sensitivity of the ELISPOT-technique. In
contrast to short-term ELISPOT assays which detect only the
rapidly reacting allo-reactive memory T cells [23], the CFSE-MLR
Figure 7. Comparison of IFN-c production by T cells in CFSE-MLR before and 1 year after LTx. CFSE-labeled PBMC from 5 LTx-patients
were stimulated with donor-derived or 3rd party CD40-B cells, and re-stimulated with the same allo-antigens at day 5 of culture for 24 hours. During
the last 15 hours Brefeldin A was added, and CFSE-dilution and intracellular IFN-c was determined at day 6. Depicted are the percentages of T cells
producing IFN-c in response to donor-derived CD40-B cells and 3rd party-derived CD40-B cells, and the RR of IFN-c producing T cells. No statistically
significant differences were observed in comparing RR at 1 year after LTx versus before LTx (p$0.44).
doi:10.1371/journal.pone.0014452.g007
Figure 6. Longitudinal course of circulating donor-specific T-cell precursor frequencies in LTx-recipients. CFSE-labeled PBMC of 13 LTx-
recipients obtained before transplantation (Pre), or at 1 week (W1), 1 month (M1), 3 months (M3) or 1 year (Y1) after transplantation, were co-cultured
for 6 days with donor-derived splenic CD40-B cells, 3rd party splenic CD40-B cells or autologous PBMC-derived CD40-B cells. PF of CD3+, CD4+ and
CD8+ T cells responding to these stimulators were determined. Recipients and donors differed on the average in 1.5 HLA-AB alleles and in 1.7 HLA-DR
alleles. Third-party stimulators were mismatched with recipients in 1.7 HLA-AB alleles and 1.8 HLA-DR alleles. Donor-derived and 3rd party-derived
stimulator cells differed on the average at 1.8 HLA-AB loci and 1.5 HLA-DR loci. A. Numbers of T-cell precursors responding to donor-derived CD40-B
cells increased significantly 1 week after transplantation in all T-cell subsets, followed by a decrease to values below pre-transplant levels. B. Non-
specific variations in allo-responses were determined by stimulating patient PBMC with third-party spleen-derived CD40-B cells. Changes in PF of
CD4+ and CD8+ T cells responding to 3rd party CD40-B cells between subsequent time points were generally smaller compared to those in donor-
specific PF. C. Donor-specific responses were calculated by dividing PF responding to donor-alloantigen by third-party PF to obtain the relative
responses (RR). RR increased significantly 1 week after transplantation in all T-cell subsets, followed by a significant decrease at 1 year after LTX. D.
Comparison of relative CD3+, CD4+ and CD8+ T-cell responses (RR) of 18 LTx-recipients before and 1 year after LTx. Five additional patients were
analyzed, and their data were added to the data of the 13 patients shown in C. Donor-derived and 3rd party-derived stimulator cells used in assaying
the 5 additional patients were fully MHC mismatched.
doi:10.1371/journal.pone.0014452.g006
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detects allo-reactive precursors in memory and naı¨ve T cells
simultaneously. Because the allo-reactive repertoire contains both
naive and memory T cells [10,47,48], we judge that simultaneous
quantification of both subsets is an advantage of the current
technique compared to ELISPOT. Together, these differences may
explain why published PF of donor-specific T cells in human organ
transplant recipients detected by LDA [8,9,10,13,49,50] or ELI-
SPOT [22,23,51,52,53] are significantly lower compared to those
observed in this study with the CFSE-MLR. Importantly, the use of
CD40-B cells as stimulators to detect allogeneic T-cell responses
[54], and CFSE-dilution as a technique to measure the proliferative
response of T cells to allo-antigens [17,24,25,46,47] have both been
described, but to our best knowledge these techniques have never
been combined.
It is generally assumed that recipient T-cell responses against
directly presented donor allo-antigen peak shortly after transplan-
tation [2], but this has never been formally proven in humans. So
far, the only other study that quantified donor-specific T-cell
responses longitudinally after human organ transplantation [51]
actually found a nadir in frequencies of donor-specific T cells at 1
week after kidney transplantation using IFN-c ELISPOT. We
observed, after correction for changes in responses to 3rd party
allo-antigens, a significant, but modest, increase of circulating
donor-specific CD4+ and CD8+ T-cell numbers immediately after
LTx, followed by a decrease to levels equal to numbers of T cells
responding to 3rd party allo-antigens within the first year. This
increase was not due to variations in immunosuppression, because
it was corrected for variations in 3rd party responses. Moreover,
the highest blood trough concentrations of the calcineurin
inhibitors CsA and Tacrolimus were observed in these patients
at 1 week after LTx, after which they gradually decreased (data
not shown), indicating that the increase of numbers of donor-
specific T cells during the first week after LTx occurred despite
high levels of immunosuppressive drugs, and that the decrease
afterwards was not the consequence of increasing levels of
immunosuppressive drugs. The observed increase in T-cell PF
reacting to 3rd party allo-antigens, which was smaller compared to
the increase in donor-specific T-cell PF, may be explained by
partial overlap in HLA between donor and 3rd party stimulator
cells spleen CD40-B cells. Due to limited availability of banked
splenocytes, complete HLA mismatching between donor and 3rd
party stimulators was not always possible. Our results are
congruent with recent observations in mice showing a significant
increase in direct pathway donor-specific T-cells shortly after
transplantation [55], which is probably related to migration of
donor-derived dendritic cells from the graft into the recipient [7].
With LDA, it has repeatedly been shown that after organ
transplantation in humans, numbers of circulating donor-specific
T cells decrease below pre-transplant values and below numbers of
T cells responding to 3rd party allo-antigens [8,9,10,11,13,22,39].
Donor-specific hypo-responsiveness was already observed at 1
month after LTx [13]. This phenomenon was attributed to
induction of anergy in donor-specific T cells [56] or to suppression
exerted by CD4+Foxp3+ regulatory T cells [11]. Of notice, donor-
specific hypo-responsiveness in cytotoxic T-cell PF detected by
LDA after lung transplantation, could not be confirmed using
flow-cytometric detection of CD8+ T-cell activation and IFN-c
production [57]. Therefore, our observation that no loss of donor-
specific T-cells occurs after LTx is probably due the higher
sensitivity of the CFSE-MLR compared to LDA. Re-stimulation of
CFSE-labeled recipient T cells during the last day of culture with
CD40-B cells of the same donor allowed quantification of effector
function (IFN-c production) of responding T cells. The data
revealed that there is a decrease in the proportions of recipient T-
cells producing IFN-c at 1 year after LTx compared to pre-LTx
values. This decrease, however, occurred both upon stimulation
with donor-derived and with 3rd party-derived CD40-B cells,
demonstrating that no donor-specific loss of T-cell functionality
occurs after LTx. We suppose that the non-specific decrease in the
capacity of T cells to produce IFN-c after LTx is probably due to
the continuous treatment with immunosuppressive medication. In
summary, our data show that no specific loss of circulating donor-
specific T-cell clones occurs during the first year after LTx, that
their capacity to expand in response to donor allo-antigens is
undisturbed, and that they are still able to mount effector function
although at a lower level because of a general impairment of T-cell
effector function. These conclusions are consistent with those of
Kusaka et al [58], who showed high levels of donor HLA-specific
T-cell clonotype mRNAs in PBMC late after renal transplantation.
Both studies imply that T cells which recognize donor allo-
antigens via the direct pathway remain present in the recipient
circulation for at least one year after transplantation. Whether
donor-specific hypo-responsiveness might develop later after
transplantation will be subject of a future study.
Of the 18 patients studied in the current paper, 4 experienced
one or more episodes of acute rejection, occurring between day 10
and day 60 after LTx. The data show some tendency of higher
pre-LTx CD3+ and CD8+ donor-specific T-cell PF in the patients
which developed acute rejection, but this difference is statistically
not significant. The present study was not designed for studying
differences between rejectors and non-rejectors, neither powered
for that purpose. Associations between donor-specific T-cell PF
and acute or chronic rejection will be the subject of a later study
with larger numbers of patients.
In conclusion, by using a novel technical approach, we showed for
the first time an increase of donor-specific T-cell frequencies shortly
after LTx in humans. In addition, we observed that T cells reacting to
donor allo-antigens presented via the direct pathway remain present
in the recipient circulation for at least 1 year after transplantation.
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